Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry

Figures

• 

  Fig. 1. Flow chart of the study population. AF, atrial fibrillation; CKD, chronic kidney disease; DOAC, direct-acting oral anticoagulant; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; OAC, oral anticoagulant.

• 

  Fig. 2. Event rates and HRs of adverse clinical outcomes for DOAC versus warfarin in AF patients with advanced CKD or ESRD on dialysis. Event rate is calculated for 100 person-years. AF, atrial fibrillation; CI, confidence interval; CKD, chronic kidney disease; CLI, critical limb ischemia; CRNM, clinically relevant non-major; DOAC, direct-acting oral anticoagulant; ESRD, end-stage renal disease; HR, hazard ratio.

• 

  Fig. 3. Event rates and HRs of adverse clinical outcomes for DOAC versus no OAC in AF patients with advanced CKD or ESRD on dialysis. Event rate is calculated for 100 person-years. AF, atrial fibrillation; CI, confidence interval; CKD, chronic kidney disease; CLI, critical limb ischemia; CRNM, clinically relevant non-major; DOAC, direct-acting oral anticoagulant; ESRD, end-stage renal disease; HR, hazard ratio; OAC, oral anticoagulant.

• 

  Fig. 4. Survival curves for adverse clinical outcomes in the DOAC, warfarin, and no OAC groups in AF patients with advanced CKD or ESRD on dialysis. AF, atrial fibrillation; CKD, chronic kidney disease; CLI, critical limb ischemia; CRNM, clinically relevant non-major; DOAC, direct-acting oral anticoagulant; ESRD, end-stage renal disease; OAC, oral anticoagulant.